A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy

Sponsor
University Hospital, Bordeaux
Study ID
NCT01245660
Phase
EARLY_PHASE1
Status
Terminated

Conditions

  • Bladder Carcinoma
  • Cystectomy
  • Infiltrative Bladder Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • LAPATINIB — DRUG
    Lapatinib, 1250 mg per day, per os, during 3 weeks +/- 5 days.

Study Details

Modification of the EGF signalling pathway and / or HER 2, by Lapatinib in bladder cancer.

Key Dates

First listed
Nov 22, 2010
Start date
Jan 31, 2011
Status verified
Jan 2013
Primary completion
Oct 31, 2011
Completion
Oct 31, 2011

Study Design

Enrollment
3 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP

Arms

  • Experimental: Patient

Primary Outcome Measure

Effect on egf pathway at a molecular level of 3 weeks treatment by lapatinib. [ Time Frame: At surgery (day 21-27) ]

Related Studies